Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial

被引：0
|
作者：
Mullin, K. [1 ]
Croop, R. [2 ]
Pavlovic, J. [3 ]
Mosher, L. [2 ]
Smith, T. [4 ]
Madonia, J. [2 ]
Lovegren, M. [2 ]
Coric, V. [2 ]
Lipton, R. [3 ]
机构：
[1] New England Inst Neurol & Headache, Stamford, CT USA
[2] Biohaven Pharmaceut, New Haven, CT USA
[3] Albert Einstein Coll Med, Bronx, NY 10467 USA
[4] Study Metrix Res, St Peters, MO USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2022年 / 23卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P136a
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, Kathleen
    Croop, Robert
    Pavlovic, Jelena M.
    Mosher, Linda
    Smith, Timothy R.
    Madonia, Jennifer
    Lovegren, Meghan
    Coric, Vladimir
    Lipton, Richard B.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 126 - 127
  • [2] Efficacy and safety of zavegepant nasal spray for the acute treatment of migraine: Results of a phase 3 double-blind, randomized, placebo controlled trial
    Mullin, K.
    Croop, R.
    Pavlovic, J. M.
    Mosher, L.
    Smith, T. R.
    Madonia, J.
    Lovegren, M.
    Coric, V
    Lipton, R. B.
    HEADACHE, 2022, 62 : 128 - 129
  • [3] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, Kathleen
    Croop, Robert
    Pavlovic, Jelena
    Mosher, Linda
    Smith, Timothy
    Madonia, Jennifer
    Lovegren, Meghan
    Lipton, Richard
    NEUROLOGY, 2023, 100 (17)
  • [4] Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial
    Croop, Robert
    Madonia, Jennifer
    Stock, David A.
    Thiry, Alexandra
    Forshaw, Micaela
    Murphy, Abigail
    Coric, Vladimir
    Lipton, Richard B.
    HEADACHE, 2022, 62 (09): : 1153 - 1163
  • [5] Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA : a phase 3, double-blind, randomised, placebo-controlled multicentre trial
    Lipton, Richard B.
    Croop, Robert
    Stock, David A.
    Madonia, Jennifer
    Forshaw, Micaela
    Lovegren, Meghan
    Mosher, Linda
    Coric, Vladimir
    Goadsby, Peter J.
    LANCET NEUROLOGY, 2023, 22 (03):
  • [6] Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial (vol 22, pg 209, 2023)
    Lipton, R. B.
    Croop, R.
    Stock, D. A.
    LANCET NEUROLOGY, 2023, 22 (05): : e7 - e7
  • [7] A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents
    Winner, P
    Rothner, AD
    Saper, J
    Nett, R
    Asgharnejad, M
    Laurenza, A
    Austin, R
    Peykamian, M
    PEDIATRICS, 2000, 106 (05) : 989 - 997
  • [8] Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial
    Silberstein, Stephen D.
    Lipton, Richard B.
    Dodick, David W.
    Freitag, Frederick G.
    Ramadan, Nabih
    Mathew, Ninan
    Brandes, Jan L.
    Bigal, Marcelo
    Saper, Joel
    Ascher, Steven
    Jordan, Donna M.
    Greenberg, Steven J.
    Hulihan, Joseph
    HEADACHE, 2007, 47 (02): : 170 - 180
  • [9] Efficacy and safety of STS101 DHE nasal powder for the acute treatment of migraine: Results from the Phase 3 double-blind, randomized, placebo-controlled SUMMIT study
    Lipton, R.
    Tepper, S.
    Albrecht, D.
    HEADACHE, 2023, 63 : 112 - 113
  • [10] A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
    Voss, Tiffini
    Lipton, Richard B.
    Dodick, David W.
    Dupre, Nicole
    Ge, Joy Yang
    Bachman, Robert
    Assaid, Christopher
    Aurora, Sheena K.
    Michelson, David
    CEPHALALGIA, 2016, 36 (09) : 887 - 898
12345